JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Currier, R. D.
Right arrow Articles by Meydrech, E. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Currier, R. D.
Right arrow Articles by Meydrech, E. F.

Journal of Neurology, Neurosurgery, and Psychiatry, 1993, Vol 56, 1217-1218

PAPERS

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study [published erratum appears in J Neurol Neurosurg Psychiatry 1994 Apr;57(4):528]

RD Currier, AF Haerer and EF Meydrech
Department of Neurology, University of Mississippi Medical Center, Jackson 39216.

An 18-month double-blind treatment of multiple sclerosis with low dose oral methotrexate showed it to be well tolerated and suggested effectiveness in exacerbating-remitting MS but not in the exacerbating progressive and chronic progressive stages.

© 1993 by Journal of Neurology, Neurosurgery, and Psychiatry



This article has been cited by other articles:


Home page
 Mult SclerHome page
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al.
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
Multiple Sclerosis, April 1, 2008; 14(3): 370 - 382.
[Abstract] [PDF]

Home page
 Mult SclerHome page
O M Gray, G V McDonnell, and R B Forbes
A systematic review of oral methotrexate for multiple sclerosis
Multiple Sclerosis, August 1, 2006; 12(4): 507 - 510.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al.
Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations
Arch Neurol, October 1, 2005; 62(10): 1519 - 1530.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
L. Kappos
Effect of drugs in secondary disease progression in patients with multiple sclerosis
Multiple Sclerosis, June 1, 2004; 10(1_suppl): S46 - S55.
[Abstract] [PDF]

Home page
 Mult SclerHome page
L. Kappos
Effect of drugs in secondary disease progression in patients with multiple sclerosis
Multiple Sclerosis, May 1, 2004; 10(3_suppl): S46 - S55.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J Bryant, A Clegg, and R Milne
Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?
J. Neurol. Neurosurg. Psychiatry, May 1, 2001; 70(5): 574 - 579.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1993 by the BMJ Publishing Group Ltd.